DK0853480T3 - Anvendelse af en thienotriazolodiazepin til forøgelse af apolipoprotein A-I-niveauer - Google Patents

Anvendelse af en thienotriazolodiazepin til forøgelse af apolipoprotein A-I-niveauer

Info

Publication number
DK0853480T3
DK0853480T3 DK96930137T DK96930137T DK0853480T3 DK 0853480 T3 DK0853480 T3 DK 0853480T3 DK 96930137 T DK96930137 T DK 96930137T DK 96930137 T DK96930137 T DK 96930137T DK 0853480 T3 DK0853480 T3 DK 0853480T3
Authority
DK
Denmark
Prior art keywords
pct
levels
thienotriazolodiazepine
sec
date
Prior art date
Application number
DK96930137T
Other languages
Danish (da)
English (en)
Inventor
Herman Kempen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK0853480T3 publication Critical patent/DK0853480T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK96930137T 1995-09-09 1996-08-30 Anvendelse af en thienotriazolodiazepin til forøgelse af apolipoprotein A-I-niveauer DK0853480T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95114163 1995-09-09
PCT/EP1996/003814 WO1997009048A1 (en) 1995-09-09 1996-08-30 Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels

Publications (1)

Publication Number Publication Date
DK0853480T3 true DK0853480T3 (da) 2003-05-05

Family

ID=8219597

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96930137T DK0853480T3 (da) 1995-09-09 1996-08-30 Anvendelse af en thienotriazolodiazepin til forøgelse af apolipoprotein A-I-niveauer

Country Status (14)

Country Link
US (1) US5854238A (OSRAM)
EP (1) EP0853480B1 (OSRAM)
JP (1) JPH11512107A (OSRAM)
KR (1) KR19990044460A (OSRAM)
CN (1) CN1101680C (OSRAM)
AT (1) ATE230600T1 (OSRAM)
AU (1) AU725249B2 (OSRAM)
BR (1) BR9610390A (OSRAM)
CA (1) CA2230477A1 (OSRAM)
DE (1) DE69625696T2 (OSRAM)
DK (1) DK0853480T3 (OSRAM)
ES (1) ES2188783T3 (OSRAM)
TR (1) TR199800406T1 (OSRAM)
WO (1) WO1997009048A1 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6253569B1 (en) * 1999-05-07 2001-07-03 James J. Hall Portable storage unit for game animals
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US20040235877A1 (en) 2001-09-14 2004-11-25 Natsuki Ishizuka Novel use of tricyclic compound
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
NZ555826A (en) 2004-12-06 2009-11-27 Univ California Methods for improving the structure and function of arterioles
WO2009032702A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US9422363B2 (en) 2007-08-28 2016-08-23 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EA018620B1 (ru) * 2008-10-30 2013-09-30 Сёркомед Ллк ПРОИЗВОДНЫЕ ТИЕНОТРИАЗОЛОДИАЗЕПИНА, АКТИВНЫЕ В ОТНОШЕНИИ Apo A1
CA2799420C (en) 2010-05-14 2018-10-02 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
CA2799373A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
JP2016531113A (ja) 2013-07-25 2016-10-06 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 転写因子の阻害剤およびその使用
MX379463B (es) 2013-11-08 2025-03-10 Dana Farber Cancer Inst Inc Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
RU2722179C2 (ru) 2014-02-28 2020-05-28 Тэнша Терапеутикс, Инк. Лечение состояний, ассоциированных с гиперинсулинемией
USRE50320E1 (en) 2014-07-31 2025-03-04 Uab Research Foundation APOE mimetic peptides and higher potency to clear plasma cholesterol
KR20170032474A (ko) 2014-08-08 2017-03-22 다나-파버 캔서 인스티튜트 인크. 디히드로프테리디논 유도체 및 그의 용도
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
BR112017008714A2 (pt) 2014-10-27 2017-12-19 Tensha Therapeutics Inc inibidores de bromodomínio
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
KR20180049058A (ko) 2015-09-11 2018-05-10 다나-파버 캔서 인스티튜트 인크. 시아노 티에노트리아졸로디아제핀 및 그의 용도
CA2996977A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
EA202092635A1 (ru) 2018-06-13 2021-03-23 Дибли Аг Получение конденсированных производных триазепина и их применение в качестве ингибиторов bet

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
PH12303A (en) * 1973-02-08 1979-01-16 Hoffmann La Roche Thienotriazolodiazepine derivatives
JPS50100096A (OSRAM) * 1974-01-08 1975-08-08

Also Published As

Publication number Publication date
BR9610390A (pt) 1999-07-06
EP0853480B1 (en) 2003-01-08
EP0853480A1 (en) 1998-07-22
CN1101680C (zh) 2003-02-19
KR19990044460A (ko) 1999-06-25
CA2230477A1 (en) 1997-03-13
AU725249B2 (en) 2000-10-12
DE69625696D1 (de) 2003-02-13
DE69625696T2 (de) 2003-10-16
CN1195989A (zh) 1998-10-14
AU6930396A (en) 1997-03-27
MX9801753A (es) 1998-08-30
JPH11512107A (ja) 1999-10-19
ES2188783T3 (es) 2003-07-01
US5854238A (en) 1998-12-29
TR199800406T1 (en) 1998-05-21
WO1997009048A1 (en) 1997-03-13
ATE230600T1 (de) 2003-01-15

Similar Documents

Publication Publication Date Title
DK0853480T3 (da) Anvendelse af en thienotriazolodiazepin til forøgelse af apolipoprotein A-I-niveauer
GR960100438A (el) Νεα παρασιτοκτονα.
TR199901276T2 (xx) Farnezil protein transferaz inhibisyonu i�in yararl� bile�ikler.
ES2142593T3 (es) Poliuretanos altamente funcionalizados.
ATE182892T1 (de) Mercaptoacetylamide von pyridazo(1,2-a>(1,2>- diazepin -derivaten als eukephalinase und ace- inhibitoren
NZ324921A (en) Cathepsin K crystal structure and methods of identifying inhibitors of this protease
CA2174494A1 (en) Benzofurans
BG102259A (en) Compostions with controlled paroxetine release
ZA964097B (en) New variant of apolipoprotein a-i
FI973221A0 (fi) 1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
DE69616074D1 (de) Ara-c derivate
ATE244712T1 (de) Piperazino-derivative als neurokininantagonisten
DK0804079T3 (da) Algicidkombination
NO20003397L (no) 3 '-epimerie K-252A-derivater
DE60031269D1 (de) Halbsynthese von paclitaxel mit hilfe von dialkyldichlorsilanen
DE69619530D1 (de) Zyklische somatostatinanaloge mit wachstumhormon inhibierender aktivität
SE9301831D0 (sv) Pharmaceutical compositions
DK0825859T3 (da) Anvendelse af forskolin eller ekstrakter indeholdende dette til fremstilling af et lægemiddel til behandling af alkoholafhængighed
NL1002352A1 (nl) Groep bestratingsstenen.
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
TR199800850T2 (xx) Kan� d�zenleyici bile�imler.
EP0624587A3 (de) Asymmetrische Hydrierung von Furoimidazol-derivaten.
SE9500500D0 (sv) Inhibtion of the growth of E. coli
ATE160782T1 (de) Fluoro-nukleosid-reinigung
BR9607577A (pt) Método para inibir catepsina k